Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other brokerages also recently commented on EPRX. Cantor Fitzgerald lifted their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $15.50.

Eupraxia Pharmaceuticals Stock Up 4.7%

NASDAQ EPRX opened at $8.50 on Friday. The business’s fifty day simple moving average is $8.02 and its 200-day simple moving average is $6.56. The firm has a market cap of $305.66 million, a PE ratio of -9.77 and a beta of 1.20. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $9.32.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Guardian Wealth Advisors LLC NC acquired a new position in Eupraxia Pharmaceuticals during the 4th quarter worth about $76,000. Aptus Capital Advisors LLC purchased a new stake in Eupraxia Pharmaceuticals during the fourth quarter worth about $76,000. Bank of America Corp DE lifted its position in shares of Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Eupraxia Pharmaceuticals during the second quarter worth about $61,000. Finally, TCI Wealth Advisors Inc. purchased a new position in shares of Eupraxia Pharmaceuticals in the third quarter valued at approximately $65,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.